ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Toxic soluble oligomers

<< Previous

Bullboard Posts

Next >>

Comment by Gbathaton Oct 20, 2024 9:05pm

141 Views

Post# 36274062

RE:RE:RE:RE:RE:RE:Toxic soluble oligomers

safety data from Ph1a was not from AD patients

Ph1b will be the first look at ARIA avoidance in vivo

All previous data was in-vitro (lab bench showing no binding to plaque)

Also, I think a bi-monthly treatment might be preferable to taking pills twice a day, especially for those on other oral meds... interactions, naseaua, ulcers, etc might make popping pills twice daily less attractive, particularly for those with cognitive issues.

PMN is still in it to win it

<< Previous

Bullboard Posts

Next >>

Advancing flagship Ishkõday Gold Project in Ontario